# Lucid Diagnostics Inc.: financial statements, quarterly

LUCD · Nasdaq · CIK 1799011 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lucd.md) · [Financials](/companies/lucd/financials.md) · [Filings](/companies/lucd/filings.md) · [Insiders](/companies/lucd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lucd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.8](/filings/0001493152-24-044799.md) | [1.0 d](/filings/0001641172-25-000205.md) | [1.0](/filings/0001641172-25-009986.md) | [1.0](/filings/0001493152-25-011862.md) | [1.2](/filings/0001493152-25-021737.md) | [1.2 d](/filings/0001641172-25-000205.md) | [0.8](/filings/0001641172-25-009986.md) | [1.2](/filings/0001493152-25-011862.md) | [1.2](/filings/0001493152-25-021737.md) | [1.5 d](/filings/0001437749-26-009805.md) | [1.3](/filings/0001437749-26-016751.md) | [1.5](/filings/0001437749-26-027335.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [1.6](/filings/0001437749-26-016751.md) | [1.6](/filings/0001437749-26-027335.md) | not reported | not reported | [1.6](/filings/0001437749-26-016751.md) | [1.4](/filings/0001437749-26-027335.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.6](/filings/0001493152-24-044799.md) | [1.9 d](/filings/0001641172-25-000205.md) | [1.5](/filings/0001641172-25-009986.md) | [1.4](/filings/0001493152-25-011862.md) | [1.7](/filings/0001493152-25-021737.md) | [1.5 d](/filings/0001437749-26-009805.md) | [1.4](/filings/0001437749-26-016751.md) | [1.3](/filings/0001437749-26-027335.md) | [1.3](/filings/0001493152-25-021737.md) | [1.7 d](/filings/0001437749-26-009805.md) | [1.2](/filings/0001437749-26-016751.md) | [1.2](/filings/0001437749-26-027335.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(11.1)](/filings/0001493152-24-044799.md) | [(11.5) d](/filings/0001641172-25-000205.md) | [(10.8)](/filings/0001641172-25-009986.md) | [(11.2)](/filings/0001493152-25-011862.md) | [(11.7)](/filings/0001493152-25-021737.md) | [(12.4) d](/filings/0001437749-26-009805.md) | [(12.5)](/filings/0001437749-26-016751.md) | [(11.4)](/filings/0001437749-26-027335.md) | [(11.8)](/filings/0001493152-25-021737.md) | [(14.0) d](/filings/0001437749-26-009805.md) | [(12.1)](/filings/0001437749-26-016751.md) | [(12.8)](/filings/0001437749-26-027335.md) |
| Interest expense | $m | [0.1](/filings/0001493152-24-044799.md) | [0.0 d](/filings/0001641172-25-000205.md) | [0.0](/filings/0001641172-25-009986.md) | [0.0](/filings/0001493152-25-011862.md) | [0.0](/filings/0001493152-25-021737.md) | [0.0 d](/filings/0001641172-25-000205.md) | [0.0](/filings/0001641172-25-009986.md) | [0.0](/filings/0001493152-25-011862.md) | [0.0](/filings/0001493152-25-021737.md) | [0.0 d](/filings/0001437749-26-009805.md) | [0.0](/filings/0001437749-26-016751.md) | [0.0](/filings/0001437749-26-027335.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-26-016751.md) | [0.0](/filings/0001437749-26-027335.md) | not reported | not reported | [0.0](/filings/0001437749-26-016751.md) | [0.0](/filings/0001437749-26-027335.md) |
| Net income | $m | [(14.2)](/filings/0001493152-24-044799.md) | [(10.8) d](/filings/0001641172-25-000205.md) | [(10.6)](/filings/0001641172-25-009986.md) | [(11.0)](/filings/0001493152-25-011862.md) | [(12.4)](/filings/0001493152-25-021737.md) | [(11.5) d](/filings/0001437749-26-009805.md) | [(26.9)](/filings/0001437749-26-016751.md) | [(4.4)](/filings/0001437749-26-027335.md) | [(10.4)](/filings/0001493152-25-021737.md) | [(16.3) d](/filings/0001437749-26-009805.md) | [(13.9)](/filings/0001437749-26-016751.md) | [(11.7)](/filings/0001437749-26-027335.md) |
| Diluted EPS | $ per share | [(0.34)](/filings/0001493152-24-044799.md) | not reported | [(0.40)](/filings/0001641172-25-009986.md) | [(0.23)](/filings/0001493152-25-011862.md) | [(0.25)](/filings/0001493152-25-021737.md) | not reported | [(0.52)](/filings/0001641172-25-009986.md) | [(0.08)](/filings/0001493152-25-011862.md) | [(0.10)](/filings/0001493152-25-021737.md) | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.34)](/filings/0001493152-24-044799.md) | not reported | [(0.40)](/filings/0001641172-25-009986.md) | [(0.23)](/filings/0001493152-25-011862.md) | [(0.25)](/filings/0001493152-25-021737.md) | not reported | [(0.52)](/filings/0001437749-26-016751.md) | [(0.08)](/filings/0001437749-26-027335.md) | [(0.10)](/filings/0001493152-25-021737.md) | not reported | [(0.17)](/filings/0001437749-26-016751.md) | [(0.08)](/filings/0001437749-26-027335.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [24.1](/filings/0001493152-23-040623.md) | [18.9](/filings/0001641172-25-000205.md) | [24.8](/filings/0001493152-24-018800.md) | [24.9](/filings/0001493152-24-031168.md) | [14.5](/filings/0001493152-24-044799.md) | [22.4](/filings/0001493152-25-021737.md) | [25.2](/filings/0001641172-25-009986.md) | [31.1](/filings/0001493152-25-011862.md) | [47.3](/filings/0001493152-25-021737.md) | [34.7](/filings/0001437749-26-027335.md) | [27.9](/filings/0001437749-26-016751.md) | [33.4](/filings/0001437749-26-027335.md) |
| Current assets | $m | [27.3](/filings/0001493152-23-040623.md) | [22.1](/filings/0001641172-25-000205.md) | [27.6](/filings/0001493152-24-018800.md) | [27.9](/filings/0001493152-24-031168.md) | [16.8](/filings/0001493152-24-044799.md) | [25.1](/filings/0001437749-26-009805.md) | [27.5](/filings/0001641172-25-009986.md) | [33.8](/filings/0001493152-25-011862.md) | [49.8](/filings/0001493152-25-021737.md) | [37.5](/filings/0001437749-26-027335.md) | [31.4](/filings/0001437749-26-016751.md) | [36.6](/filings/0001437749-26-027335.md) |
| Total assets | $m | [33.2](/filings/0001493152-23-040623.md) | [27.3](/filings/0001641172-25-000205.md) | [32.0](/filings/0001493152-24-018800.md) | [34.1](/filings/0001493152-24-031168.md) | [22.6](/filings/0001493152-24-044799.md) | [30.7](/filings/0001437749-26-009805.md) | [32.8](/filings/0001641172-25-009986.md) | [38.7](/filings/0001493152-25-011862.md) | [53.2](/filings/0001493152-25-021737.md) | [40.4](/filings/0001437749-26-027335.md) | [34.1](/filings/0001437749-26-016751.md) | [38.9](/filings/0001437749-26-027335.md) |
| Current liabilities | $m | [30.2](/filings/0001493152-23-040623.md) | [29.4](/filings/0001641172-25-000205.md) | [20.0](/filings/0001493152-24-018800.md) | [16.0](/filings/0001493152-24-031168.md) | [14.2](/filings/0001493152-24-044799.md) | [23.5](/filings/0001437749-26-009805.md) | [36.6](/filings/0001641172-25-009986.md) | [29.4](/filings/0001493152-25-011862.md) | [26.2](/filings/0001493152-25-021737.md) | [28.6](/filings/0001437749-26-027335.md) | [29.4](/filings/0001437749-26-016751.md) | [27.5](/filings/0001437749-26-027335.md) |
| Total liabilities | $m | [30.7](/filings/0001493152-23-040623.md) | [29.6](/filings/0001641172-25-000205.md) | [20.2](/filings/0001493152-24-018800.md) | [18.1](/filings/0001493152-24-031168.md) | [16.3](/filings/0001493152-24-044799.md) | [25.3](/filings/0001437749-26-009805.md) | [38.2](/filings/0001641172-25-009986.md) | [30.8](/filings/0001493152-25-011862.md) | [27.4](/filings/0001493152-25-021737.md) | [29.5](/filings/0001437749-26-027335.md) | [30.1](/filings/0001437749-26-016751.md) | [28.0](/filings/0001437749-26-027335.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [2.6](/filings/0001493152-24-044799.md) | [(2.3)](/filings/0001437749-26-009805.md) | [11.9](/filings/0001493152-25-011862.md) | [16.0](/filings/0001493152-25-021737.md) | [6.3](/filings/0001493152-25-021737.md) | [5.4](/filings/0001437749-26-027335.md) | [(5.4)](/filings/0001437749-26-027335.md) | [7.9](/filings/0001437749-26-027335.md) | [25.8](/filings/0001493152-25-021737.md) | [10.9](/filings/0001437749-26-027335.md) | [4.0](/filings/0001437749-26-027335.md) | [10.9](/filings/0001437749-26-027335.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.8) d](/filings/0001493152-24-044799.md) | [(10.0) d](/filings/0001641172-25-000205.md) | [(12.6)](/filings/0001641172-25-009986.md) | [(11.5) d](/filings/0001493152-25-011862.md) | [(10.2) d](/filings/0001493152-25-021737.md) | [(9.9) d](/filings/0001437749-26-009805.md) | [(12.5)](/filings/0001437749-26-016751.md) | [(10.5) d](/filings/0001437749-26-027335.md) | [(10.9) d](/filings/0001493152-25-021737.md) | [(12.6) d](/filings/0001437749-26-009805.md) | [(12.1)](/filings/0001437749-26-016751.md) | [(11.3) d](/filings/0001437749-26-027335.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001437749-26-016751.md) | [0.0 d](/filings/0001437749-26-027335.md) | not reported | not reported | [0.2](/filings/0001437749-26-016751.md) | [0.0 d](/filings/0001437749-26-027335.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.8](/filings/0001493152-23-028577.md) | [36.4](/filings/0001493152-23-040623.md) | [41.0](/filings/0001493152-24-018800.md) | [41.8](/filings/0001493152-24-031168.md) | [41.9](/filings/0001493152-24-044799.md) | [45.0](/filings/0001641172-25-009986.md) | [48.2](/filings/0001493152-25-011862.md) | [50.4](/filings/0001493152-25-021737.md) | [68.8](/filings/0001641172-25-009986.md) | [99.0](/filings/0001493152-25-011862.md) | [108](/filings/0001493152-25-021737.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 203,243,970 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001437749-26-027335.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.